Drug Profile
AU 101
Alternative Names: AU101Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Aurora BioPharma
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glioblastoma; Osteosarcoma
- Preclinical HER2 positive breast cancer
Most Recent Events
- 05 Sep 2023 AU 101 is still in preclinical trials for HER2-positive-breast-cancer in USA (Parenteral) (Aurora Biopharma pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 12 Jul 2016 Phase-I/II clinical trials in Glioblastoma (Second-line therapy or greater) (Parenteral) before July 2016